Immune Checkpoint Blockade in Advanced Renal-Cell Carcinoma

In the CheckMate 214 trial, Motzer et al found higher overall survival among intermediate- and poor-risk patients with previously untreated metastatic renal-cell carcinoma who received nivolumab plus ipilimumab than among those who received sunitinib07/05/2018
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news